VS 01

Drug Profile

VS 01

Alternative Names: VS-01

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Versantis
  • Class Tricarboxylic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Liver failure

Most Recent Events

  • 17 Jul 2017 VS 01 receives Orphan Drug status for Liver failure (Acute-on-Chronic) in USA
  • 30 Nov 2016 VS 01 receives Orphan Drug status for Liver failure before November 2016 (Versantis website, November 2016)
  • 01 Mar 2016 Preclinical trials in Inborn urea cycle disorders in Switzerland (Intraperitoneal) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top